{
    "clinical_study": {
        "@rank": "104338", 
        "arm_group": [
            {
                "arm_group_label": "MK-1293", 
                "arm_group_type": "Experimental", 
                "description": "MK-1293 administered subcutaneously once daily at bedtime. Participants will continue their prandial insulin during the study."
            }, 
            {
                "arm_group_label": "Lantus\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "Lantus\u2122 administered subcutaneously once daily at bedtime. Participants will continue their prandial insulin during the study."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the safety and efficacy of MK-1293 to Lantus\u2122 in\n      participants with T1DM.  The primary hypothesis is that after 24 weeks, the mean change in\n      hemoglobin A1c (A1C) from baseline is non-inferior in participants treated with MK-1293\n      compared with participants treated with Lantus\u2122."
        }, 
        "brief_title": "A Study of the Safety and Efficacy of MK-1293 Compared to Lantus\u2122 in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  T1DM For at least 1 year\n\n          -  is currently using or has been using prandial insulin for at least 4 weeks.\n             Participants taking any type of basal insulin should require a total daily dose of\n             >=10 units/day. For participants currently taking pre-mixed insulin, the basal\n             insulin component should be equivalent to a total daily dose of >=10 units/day.\n\n          -  is male, or is female who is not of reproductive potential or if of reproductive\n             potential agrees to remain abstinent or use (or have their partner use) an acceptable\n             method of birth control during the study and for 14 days after the last dose of study\n             medication\n\n        Exclusion Criteria:\n\n          -  has had 1 or more severe hypoglycemic episodes associated with hypoglycemic seizure\n             or loss of consciousness within the past 6 months\n\n          -  history of ketoacidosis in the last 6 months\n\n          -  participant, as assessed by the investigator, is not appropriate for or does not\n             agree to target a fasting glucose of 70-100 mg/dL [3.9 -5.6 mmol/L].\n\n          -  history of intolerance or hypersensitivity to Lantus\u2122 or contraindication to Lantus\u2122\n             or one of its excipients\n\n          -  used a formulation of insulin glargine other than Lantus\u2122\n\n          -  has received injectable incretin-based therapy within the past 8 weeks\n\n          -  on a weight loss program and not in the maintenance phase, or has started a weight\n             loss medication within the past 8 weeks\n\n          -  has undergone bariatric surgery within the past 12 months\n\n          -  is likely to require treatment for 2 or more consecutive weeks or repeated courses of\n             corticosteroids (note: inhaled, nasal, and topical corticosteroids are permitted)\n\n          -  has undergone a surgical procedure within the past 4 weeks or has planned major\n             surgery during the study\n\n          -  has new or worsening signs or symptoms of coronary heart disease or congestive heart\n             failure within the past 3 months, or has any following disorders within the past 3\n             months: acute coronary syndrome, coronary artery intervention, stroke or transient\n             ischemic neurological disorder\n\n          -  has severe peripheral vascular disease\n\n          -  has high blood pressure\n\n          -  has chronic myopathy, or a progressive neurological or neuromuscular disorder\n\n          -  has active neuropathy\n\n          -  history of active liver disease (other than non-alcoholic hepatic steatosis),\n             including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic\n             gallbladder disease\n\n          -  has human immunodeficiency virus (HIV)\n\n          -  has a hematological disorder (such as aplastic anemia, myeloproliferative or\n             myelodysplastic syndromes, thrombocytopenia)\n\n          -  history of malignancy in the past 5 years, except for adequately treated basal cell\n             or squamous cell skin cancer, or in situ cervical cancer\n\n          -  history of melanoma, leukemia, lymphoma, or renal cell carcinoma\n\n          -  is currently being treated for hyperthyroidism or has been on a stable dose of\n             thyroid hormone replacement therapy for <6 weeks\n\n          -  is a user of recreational or illicit drugs or has had a recent history of drug or\n             alcohol abuse or dependence\n\n          -  is pregnant or breast-feeding, or is expecting to conceive or donate eggs\n\n          -  has donated blood products or has had phlebotomy of >300 mL within the past 8 weeks\n             or intends to donate blood products during the study\n\n          -  has poor mental function or works the night shift"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059161", 
            "org_study_id": "1293-003", 
            "secondary_id": "2011-003971-12"
        }, 
        "intervention": [
            {
                "arm_group_label": "MK-1293", 
                "description": "MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels.  MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.", 
                "intervention_name": "MK-1293", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lantus\u2122", 
                "description": "Lantus\u2122 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels.  Lantus\u2122 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.", 
                "intervention_name": "Lantus\u2122", 
                "intervention_type": "Drug", 
                "other_name": "Insulin glargine"
            }, 
            {
                "arm_group_label": [
                    "MK-1293", 
                    "Lantus\u2122"
                ], 
                "description": "Participants will continue their prandial insulin during the study.", 
                "intervention_name": "Prandial Insulin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Huntsville", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35801"
                    }, 
                    "name": "Call for Information (Investigational Site 0003)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mesa", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85202"
                    }, 
                    "name": "Call for Information (Investigational Site 0019)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chula Vista", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91911"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenbrae", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94904"
                    }, 
                    "name": "Call for Information (Investigational Site 0028)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tustin", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92780"
                    }, 
                    "name": "Call for Information (Investigational Site 0026)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Hills", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91307"
                    }, 
                    "name": "Call for Information (Investigational Site 0020)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boca Raton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33432"
                    }, 
                    "name": "Call for Information (Investigational Site 0017)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boynton Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33435"
                    }, 
                    "name": "Call for Information (Investigational Site 0021)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bradenton", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34208"
                    }, 
                    "name": "Call for Information (Investigational Site 0005)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooksville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34601"
                    }, 
                    "name": "Call for Information (Investigational Site 0002)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oldsmar", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34677"
                    }, 
                    "name": "Call for Information (Investigational Site 0006)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Call for Information (Investigational Site 0007)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33709"
                    }, 
                    "name": "Call for Information (Investigational Site 0011)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33606"
                    }, 
                    "name": "Call for Information (Investigational Site 0010)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roswell", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30076"
                    }, 
                    "name": "Call for Information (Investigational Site 0024)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21204"
                    }, 
                    "name": "Call for Information (Investigational Site 0012)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }, 
                    "name": "Call for Information (Investigational Site 0018)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68131"
                    }, 
                    "name": "Call for Information (Investigational Site 0014)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89148"
                    }, 
                    "name": "Call for Information (Investigational Site 0025)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bristol", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37620"
                    }, 
                    "name": "Call for Information (Investigational Site 0022)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Call for Information (Investigational Site 0023)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "Call for Information (Investigational Site 0027)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "Call for Information (Investigational Site 0015)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "El Paso", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "79925"
                    }, 
                    "name": "Call for Information (Investigational Site 0016)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77095"
                    }, 
                    "name": "Call for Information (Investigational Site 0013)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Call for Information (Investigational Site 0009)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Call for Information (Investigational Site 0008)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Renton", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98057"
                    }, 
                    "name": "Call for Information (Investigational Site 0029)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gary Jankelowitz", 
                    "phone": "61 2 8988 8246"
                }, 
                "facility": {
                    "address": {
                        "city": "North Ryde", 
                        "country": "Australia"
                    }, 
                    "name": "Merck Sharp & Dohme"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Francesca Carvajal", 
                    "phone": "57 1219109011090"
                }, 
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "MDS Colombia SAS"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Juan Marques", 
                    "phone": "52 55254819608"
                }, 
                "facility": {
                    "address": {
                        "city": "Mexico City", 
                        "country": "Mexico"
                    }, 
                    "name": "MSD"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gary Jankelowitz", 
                    "phone": "61 2 8988 8246"
                }, 
                "facility": {
                    "address": {
                        "city": "Wellington", 
                        "country": "New Zealand"
                    }, 
                    "name": "Merck Sharp & Dohme (New Zealand) Ltd.,"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Khanyi Mzolo", 
                    "phone": "27 11 655 3140"
                }, 
                "facility": {
                    "address": {
                        "city": "Midrand", 
                        "country": "South Africa"
                    }, 
                    "name": "MSD (Pty) LTD South Africa"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Colombia", 
                "Mexico", 
                "New Zealand", 
                "South Africa"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus\u2122 in Subjects With Type 1 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in hemoglobin A1c (A1C) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Proportion of participants with any confirmed positive anti-insulin antibody (AIA)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Proportion of participants with negative AIA at baseline who develop confirmed positive AIA at anytime up through Week 24", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }, 
            {
                "measure": "Change from baseline in AIA titers after 24 weeks of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Proportion of participants with confirmed AIA who develop any insulin neutralizing antibodies up through Week 24", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 24"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059161"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in A1C at Week 52", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "measure": "Mean insulin dose at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Mean insulin dose per kilogram (kg) of body weight (unit/kg) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Week 24"
            }, 
            {
                "measure": "Change from baseline in fasting plasma glucose (FPG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Proportion of participants with any confirmed positive AIA up through Week 52", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }, 
            {
                "measure": "Proportion of participants with negative AIA at baseline who develop confirmed positive AIA at any time up through Week 52", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }, 
            {
                "measure": "Change from baseline in AIA titers after 52 weeks of treatment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "measure": "Mean insulin dose at Week 52", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "Mean insulin dose per kilogram (kg) of body weight (unit/kg) at Week 52", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "measure": "Change from baseline in FPG at Week 52", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "measure": "Proportion of participants with confirmed AIA who develop any insulin neutralizing antibodies up through Week 52", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Week 52"
            }, 
            {
                "measure": "Change from Baseline in 7-point self-monitored blood glucose (SMBG) at Week 24", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Change from Baseline in 7-point SMBG at Week 52", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 52"
            }, 
            {
                "measure": "Proportion of participants attaining A1C glycemic goals of <7% and <6.5% after 24 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Proportion of participants attaining A1C glycemic goals of <7% and <6.5% after 52 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "52 weeks"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}